Dianthus Therapeutics, Inc.
DNTH
$78.86
-$0.04-0.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.04M | 3.08M | 4.85M | 6.52M | 6.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.04M | 3.08M | 4.85M | 6.52M | 6.24M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2.04M | 3.08M | 4.85M | 6.52M | 6.24M |
| SG&A Expenses | 34.31M | 31.19M | 29.53M | 26.66M | 24.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 179.97M | 143.39M | 134.77M | 123.72M | 108.10M |
| Operating Income | -177.93M | -140.31M | -129.92M | -117.20M | -101.86M |
| Income Before Tax | -162.34M | -126.35M | -114.75M | -100.73M | -84.97M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -162.34 | -126.35 | -114.75 | -100.73 | -84.97 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -162.34M | -126.35M | -114.75M | -100.73M | -84.97M |
| EBIT | -177.93M | -140.31M | -129.92M | -117.20M | -101.86M |
| EBITDA | -177.82M | -140.20M | -129.81M | -117.10M | -101.77M |
| EPS Basic | -4.11 | -3.49 | -3.25 | -2.89 | -2.60 |
| Normalized Basic EPS | -2.68 | -2.32 | -2.18 | -1.94 | -1.74 |
| EPS Diluted | -4.11 | -3.49 | -3.25 | -2.89 | -2.60 |
| Normalized Diluted EPS | -2.68 | -2.32 | -2.18 | -1.94 | -1.74 |
| Average Basic Shares Outstanding | 154.38M | 144.44M | 140.88M | 139.29M | 129.16M |
| Average Diluted Shares Outstanding | 154.38M | 144.44M | 140.88M | 139.29M | 129.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |